Cancer Cell Delivery
Cancer Cell Delivery - Related Videos
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
0 Views •
Cited by 9 •
2013
Implantation of cancer cells into the organ of origin can serve as a useful preclinical model to evaluate novel therapies. MB49 bladder carcinoma cells can be grown within the bladder following intravesical instillation. This protocol demonstrates catheterization of the mouse bladder for the purpose of tumor implantation and adenoviral delivery.
09:59
Preparation of Exosomes for siRNA Delivery to Cancer Cells
0 Views •
Cited by 105 •
2018
An exosome is a new generation of drug delivery carriers. We established an exosome isolation protocol with high yield and purity for siRNA delivery. We also encapsulated fluorescently labelled non-specific siRNA into exosomes and investigated the cellular uptake of siRNA-loaded exosomes in cancer cells.
08:02
Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
0 Views •
Cited by 40 •
2013
Rapid mechanical deformation of cells has emerged as a promising, vector-free method for intracellular delivery of macromolecules and nanomaterials. This protocol provides detailed steps on how to use the system for a broad range of applications.
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
0 Views •
Cited by 28 •
2012
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
0 Views •
Cited by 6 •
2014
The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.
FAQs
Targeting begins when a ligand or antibody recognizes a receptor that is enriched on malignant cells. This molecular interaction can increase association with the intended cell and promote endocytosis, the process by which the cell internalizes the delivery system. Researchers therefore evaluate both receptor recognition and subsequent uptake, because binding alone does not demonstrate effective intracellular delivery.
After uptake, the cargo must become available inside the cell rather than remain trapped in the internalized system. Cancer cell delivery studies therefore examine intracellular release as a distinct step from endocytosis. Poor release can limit therapeutic or diagnostic effects even when targeting and uptake appear successful, making release behavior an important design and evaluation criterion.
Enriched receptor expression does not guarantee uniform targeting across a tumor. Heterogeneous target expression can leave some malignant cells less accessible, while receptors present on nonmalignant cells may contribute to off-target delivery. Cancer cell delivery research consequently compares selectivity across cell populations and treats receptor distribution as a factor that can influence both effectiveness and unwanted exposure.
Cargo selection changes the delivery requirements. Small-molecule drugs, nucleic acids, proteins, and imaging agents may each require effective transport and intracellular availability, but their intended outcomes differ. A system designed for therapy is assessed by whether the cargo can support treatment effects, whereas an imaging-oriented system is assessed by whether it enables detection or visualization in the relevant cancer research setting.
A practical research workflow starts by identifying a tumor-associated receptor and choosing a ligand or antibody for molecular recognition. Investigators then pair that system with a selected cargo and examine cellular uptake, intracellular release, and selectivity. Comparing malignant and nonmalignant cell populations can reveal whether the design delivers its intended payload while limiting off-target effects.
Evaluation should separate delivery stages rather than rely on a single outcome. Researchers can assess receptor-dependent uptake, determine whether cargo is released inside cells, and examine treatment or imaging performance. They can also compare responses across cell types to identify off-target effects. Together, these measurements show whether limited delivery reflects poor recognition, inadequate internalization, insufficient release, or another design constraint.
Within cancer research, these systems support several complementary goals: screening therapeutic delivery strategies, developing gene-based therapies, improving tumor imaging, and studying how selectively a payload reaches malignant cells. They are also useful for evaluating off-target effects and design limitations. This broader use makes delivery analysis relevant not only to treatment development but also to diagnostic and mechanistic studies.